Redox modulation protects islets from transplant-related injury

Diabetes. 2010 Jul;59(7):1731-8. doi: 10.2337/db09-0588. Epub 2010 Apr 22.

Abstract

Objective: Because of reduced antioxidant defenses, beta-cells are especially vulnerable to free radical and inflammatory damage. Commonly used antirejection drugs are excellent at inhibiting the adaptive immune response; however, most are harmful to islets and do not protect well from reactive oxygen species and inflammation resulting from islet isolation and ischemia-reperfusion injury. The aim of this study was to determine whether redox modulation, using the catalytic antioxidant (CA), FBC-007, can improve in vivo islet function post-transplant.

Research design and methods: The abilities of redox modulation to preserve islet function were analyzed using three models of ischemia-reperfusion injury: 1) streptozotocin (STZ) treatment of human islets, 2) STZ-induced murine model of diabetes, and 3) models of syngeneic, allogeneic, and xenogeneic transplantation.

Results: Incubating human islets with catalytic antioxidant during STZ treatment protects from STZ-induced islet damage, and systemic delivery of catalytic antioxidant ablates STZ-induced diabetes in mice. Islets treated with catalytic antioxidant before syngeneic, suboptimal syngeneic, or xenogeneic transplant exhibited superior function compared with untreated controls. Diabetic murine recipients of catalytic antioxidant-treated allogeneic islets exhibited improved glycemic control post-transplant and demonstrated a delay in allograft rejection. Treating recipients systemically with catalytic antioxidant further extended the delay in allograft rejection.

Conclusions: Pretreating donor islets with catalytic antioxidant protects from antigen-independent ischemia-reperfusion injury in multiple transplant settings. Treating systemically with catalytic antioxidant protects islets from antigen-independent ischemia-reperfusion injury and hinders the antigen-dependent alloimmune response. These results suggest that the addition of a redox modulation strategy would be a beneficial clinical approach for islet preservation in syngeneic, allogeneic, and xenogeneic transplantation.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antioxidants / therapeutic use
  • Diabetes Mellitus, Experimental / drug therapy
  • Diabetes Mellitus, Experimental / surgery*
  • Graft Survival / drug effects*
  • Humans
  • Islets of Langerhans Transplantation / immunology
  • Islets of Langerhans Transplantation / methods*
  • Male
  • Metalloporphyrins / therapeutic use*
  • Mice
  • Oxidative Stress / drug effects*
  • Transplantation, Heterologous / immunology
  • Transplantation, Homologous / immunology

Substances

  • Antioxidants
  • Metalloporphyrins
  • manganese tetrakis-(N-ethyl-2 pyridyl) porphyrin